Thursday 21 November 2024

The Pharma Letter Podcast — Episode 24 — Lilly looks to lead in Alzheimer's

Biotechnology
Simon Wentworth
17 July 2023
pharma_letter_podcast_24

More on this story...

Biotechnology
The Pharma Letter Podcast — Episode 23 — AAIC preview with Eisai deputy CCO Michael Irizarry
6 July 2023
Biotechnology
Lilly breakthrough offers real hope for people with early Alzheimer's
17 July 2023
Biotechnology
New Alzheimer's antibodies: AAIC rings bell for first round face off
18 July 2023
Biotechnology
Coya Therapeutics expands COYA 302 into Alzheimer’s disease
21 February 2024


Companies featured in this story

More ones to watch >


Today's issue

EC approval for Pfizer’s Hympavzi
Biotechnology
EC approval for Pfizer’s Hympavzi
20 November 2024
Biotechnology
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Pharmaceutical
Ascentage's lisaftoclax accepted for priority review in China
20 November 2024
Biosimilars
Xbrane and Intas to jointly develop Opdivo biosimilar
20 November 2024
Pharmaceutical
Chris Boshoff takes on new role at Pfizer
20 November 2024
Biotechnology
Two Neds better than one in Jupiter’s world of moons
20 November 2024
Pharmaceutical
Cytokinetics and Bayer ink deal for aficamten in Japan
20 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.




More Features in Biotechnology

EC approval for Pfizer’s Hympavzi
20 November 2024
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Two Neds better than one in Jupiter’s world of moons
20 November 2024
JAK inhibitors redefining atopic dermatitis treatment
20 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze